Skip to main content
    M

    Madrigal Pharmaceuticals Inc (MDGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $423.96
    -3.43 (-0.80%)

    Market Cap: $9.93B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Madrigal Pharmaceuticals Inc (MDGL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Madrigal Pharmaceuticals reported revenue of $958.40M for the fiscal year ended Dec 31, 2025, up 432.1% from the year before. That year, net income was -$288.28M with a net margin of -30.1%, operating cash flow was -$189.55M and free cash flow was -$190.02M. The quarter ended Sep 30, 2026 had revenue of $431.27M and net income of $55.44M.

    Revenue and Margins

    The operating margin was -31.3% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$958.40M+432.1%100.0%-31.3%-30.1%
    Dec 2024$180.13MN/A100.0%-276.4%-258.6%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$958.40M$180.13M$0$0$0$0$0$0$0$0
    Gross profit$958.40M$180.13M$0$0$0$0$0$0$0$0
    Research and development$388.52M$236.72M$272.35M$245.44M$205.16M$184.81M$72.32M$25.39M$24.39M$15.93M
    Operating income-$300.10M-$497.88M-$380.50M-$293.57M-$242.48M-$206.67M-$94.97M-$40.68M-$32.06M-$25.22M
    Net income-$288.28M-$465.89M-$373.63M-$295.35M-$241.85M-$202.24M-$83.95M-$32.81M-$31.15M-$26.39M
    EBITDA-$294.24M-$495.09M-$377.56M-$292.31M-$241.80M-$206.10M-$94.86M-$40.39M-$31.64M-$25.22M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$431.27M$364.25M$311.34M$321.08M$287.27M$212.80M$137.25M$103.32M$62.17M$14.64M$0$770.00K
    Gross profit$431.27M$364.25M$311.34M$321.08M$287.27M$212.80M$137.25M$103.32M$62.17M$14.64M$0-$142.00K
    Operating income$55.99M-$56.31M-$92.72M-$59.61M-$113.97M-$47.20M-$79.31M-$67.00M-$116.30M-$162.54M-$152.04M-$117.18M
    Net income$55.44M-$57.94M-$94.39M-$58.58M-$114.19M-$42.28M-$73.24M-$59.42M-$106.96M-$151.97M-$147.54M-$112.19M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $340.90M exceeded cash and equivalents by $142.21M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.26B$1.04B$640.55M$362.57M$273.33M$287.00M$442.06M$485.43M$192.31M$41.21M
    Current assets$1.25B$1.03B$637.28M$361.37M$271.68M$285.16M$440.20M$485.20M$192.01M$41.21M
    Cash and equivalents$198.69M$100.02M$99.92M$331.55M$36.27M$54.00M$46.70M$57.38M$148.63M$19.14M
    Total liabilities$656.90M$287.86M$235.21M$165.18M$77.22M$47.02M$25.49M$8.44M$10.05M$4.80M
    Short-term debt$1.02M$983.00K$527.00K$602.00K$410.00K$318.00K$315.00KN/AN/AN/A
    Long-term debt$339.88M$117.57M$115.48M$49.29M$0N/AN/AN/A$0$0
    Shareholder equity$602.69M$754.38M$405.33M$197.39M$196.11M$239.97M$416.56M$476.98M$182.26M$36.41M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.43B$1.24B$1.23B$1.26B$1.36B$1.02B$996.63M$1.04B$1.07B$1.10B$1.08B$640.55M
    Total liabilities$807.45M$720.92M$683.87M$656.90M$736.73M$319.40M$285.99M$287.86M$296.11M$242.67M$231.52M$235.21M
    Cash and equivalents$514.64M$292.73M$227.03M$198.69M$295.69M$186.19M$183.65M$100.02M$232.68M$494.60M$622.52M$99.92M
    Shareholder equity$626.94M$523.72M$543.45M$602.69M$625.73M$695.98M$710.64M$754.38M$777.15M$857.12M$850.76M$405.33M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$189.55M-$455.57M-$324.23M-$224.86M-$183.92M-$157.56M-$41.62M-$25.51M-$22.32M-$17.61M
    Capital expenditures$467.00K$1.46M$1.48M$217.00K$209.00K$334.00K$172.00K$22.00K$125.00K$3.00K
    Free cash flow-$190.02M-$457.03M-$325.71M-$225.07M-$184.13M-$157.90M-$41.80M-$25.53M-$22.44M-$17.61M
    Investing cash flow$32.32M-$274.39M-$502.52M$206.69M-$5.05M$159.78M$30.71M-$380.08M-$22.01M$21.99M
    Financing cash flow$255.98M$735.06M$595.12M$313.45M$171.24M$5.09M$235.00K$314.33M$173.81M$14.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$120.56M$23.33M-$167.44M-$133.46M$79.85M-$47.05M-$88.89M-$104.49M-$66.98M-$134.94M-$149.16M-$79.93M
    Capital expenditures$3.93M$4.25M$3.85M$390.00K$857.00K$0$0$195.00K$779.00K$131.00K$357.00K$1.04M
    Free cash flow$116.63M$19.08M-$171.28M-$133.85M$78.99M-$47.05M-$88.89M-$104.68M-$67.76M-$135.08M-$149.51M-$80.97M
    Last 12 quarters

    Frequently Asked Questions About MDGL

    What is Madrigal Pharmaceuticals' annual revenue?

    Madrigal Pharmaceuticals reported revenue of $958.40M for the fiscal year ended Dec 31, 2025.

    How fast is Madrigal Pharmaceuticals' revenue growing?

    Revenue was up 432.1% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Madrigal Pharmaceuticals profitable?

    No. Madrigal Pharmaceuticals reported net income of -$288.28M for the fiscal year ended Dec 31, 2025, with a net margin of -30.1%.

    How much free cash flow does MDGL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$189.55M minus capital expenditures of $467.00K produced free cash flow of -$190.02M.

    How much debt does Madrigal Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $339.88M, short-term debt of $1.02M and cash and equivalents of $198.69M.